Research Analysts Issue Forecasts for KROS FY2028 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Leerink Partnrs upped their FY2028 earnings estimates for Keros Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($2.03) per share for the year, up from their prior forecast of ($2.04). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' FY2029 earnings at ($2.69) EPS.

KROS has been the topic of several other reports. Wells Fargo & Company increased their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. TD Cowen cut Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. William Blair downgraded Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Finally, HC Wainwright reduced their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $52.56.

Keros Therapeutics Stock Down 0.5 %

Shares of KROS traded down $0.05 during mid-day trading on Monday, hitting $10.15. 629,186 shares of the company's stock were exchanged, compared to its average volume of 1,809,531. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The firm has a fifty day moving average of $19.20 and a two-hundred day moving average of $42.63. The stock has a market cap of $411.18 million, a price-to-earnings ratio of -1.95 and a beta of 1.39.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KROS. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in Keros Therapeutics during the third quarter worth about $89,000. AlphaQuest LLC boosted its holdings in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after purchasing an additional 2,964 shares in the last quarter. Finally, LMR Partners LLP bought a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $213,000. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.